Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban prophylaxis versus placebo for prevention of venous thromboembolism in high-risk ambulatory cancer patients starting systemic therapy
2015-001630-21Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in venous thromboembolism (VTE) comparing Rivaroxaban prophylaxis with Placebo (2 arms). Primary endpoint: Primary efficacy composite endpoint. Started Oct 2015; status: completed.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2015-001630-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001630-21.